Cardioprotective effects of a selective B(2) receptor agonist of bradykinin post-acute myocardial infarct.

BACKGROUND The cardioprotective benefits of bradykinin are attributable to activation of its B(2) receptor (B(2)R)-mediated actions and abolished by B(2)R antagonists. The current experiments evaluated the cardioprotective potential of a potent, long-acting B(2)R-selective agonist peptide analogue of bradykinin, the compound NG291. METHODS We compared the… CONTINUE READING